Beyond established targets, the investigation of emerging biomarkers—such as SST2R and PSMA—highlights opportunities for drug repositioning and broadens the therapeutic arsenal in hematologic cancers. The gene discussed is FOLH1; the disease is hematopoietic and lymphoid cell neoplasm.